Lidase is an enzyme agent with proteolytic activity isolated from the testes of cattle, which has a kelloidolytic effect, which increases capillary permeability, which dissolves scar tissue.
Release form and composition
Lidaza is produced in the form of a lyophilisate, from which a solution is prepared for injection and topical use (64 IU each in vials, in a cardboard bundle 5 vials complete with 5 ampoules of solvent).
Active ingredient - hyaluronidase: in 1 bottle - 64 IU.
Solvent: procaine solution 0.5% - 5 mg or sodium chloride solution 0.9% - 2 ml.
Indications for use
- Rheumatoid arthritis (as part of complex therapy);
- Postoperative, traumatic and burn scars;
- Dupuytren's contracture;
- Nonhealing ulcers for a long time (including radiation ulcers);
- Ankylosing spondylitis, osteoarthritis, severe lumbar disc disease, stiffness and contracture of joints after injuries or inflammatory processes;
- Hematomas of soft tissues of superficial localization, scleroderma (skin manifestations), chronic tendovaginitis;
- Preparation for skin-plastic surgery for cicatricial contractions;
- Allergic rhinitis (as part of complex therapy);
- Myocardial infarction;
- Inflammatory processes in the bronchi or upper respiratory tract with symptoms of obstruction, pulmonary tuberculosis, complicated by nonspecific lesions of the bronchi;
- Arachnoiditis (as part of complex therapy);
- Traumatic lesions of the nerve plexus and peripheral nerves (neuritis, plexitis);
- Hemophthalmus, hyphema, retinopathy of various etiologies.
Lidaza can also be used to improve the absorption of drugs administered intramuscularly or subcutaneously.
- Fresh vitreous hemorrhage;
- Recent hemorrhages;
- Acute infectious and inflammatory diseases;
- Concomitant use of estrogen;
- Hypersensitivity to the components.
Additional contraindications for inhalation use of Lidaza are:
- Pulmonary hemorrhage;
- Acute intercurrent diseases;
- Pulmonary tuberculosis with severe respiratory failure;
- Malignant neoplasms.
With caution, the drug should be used during pregnancy and lactation.
Dosing and Administration
Depending on the indications, Lidaza is used subcutaneously (sc), intramuscularly (intramuscularly), externally, by inhalation, by electrophoresis into scar-modified tissue or near the site of injury, as well as subconjunctival and parabulbarno.
In traumatic lesions of the peripheral nerves and nerve plexuses, the drug is injected subcutaneously in the area of the affected nerve in 64 IU (1 ml of solution) every other day. The course of treatment consists of 12-15 injections. If necessary, repeat the course.
For cicatricial lesions, the drug is injected in a / m near the site of the lesion or under the scar tissue-altered tissues of 64 IU daily or every other day. The course of treatment is 10-20 injections.
In ophthalmology, Lidasa is administered parabulbally in the amount of 0.5 ml of the solution or subconjunctivally in the amount of 0.3 ml, as well as by electrophoresis.
In pulmonary tuberculosis, accompanied by the productive nature of inflammation, the drug is prescribed as part of complex therapy in order to increase the concentration of antibacterial agents in the lesions. It is used in the form of injections and / or inhalations. Inhalations are carried out 1 time per day, daily, using 5 ml of solution (320 IU). The general course of treatment is 20-25 inhalations. If necessary, at intervals of 1.5-2 months, the courses are repeated.
When applied by electrophoresis, the drug is administered from the anode to the affected area for 20-30 minutes. To do this, 300 IU dissolved in 60 ml of distilled water and add 2-3 drops of a 0.1% solution of hydrochloric acid. The course of treatment consists of 15-20 sessions. The prepared solution is suitable for use within 24 hours.
Outwardly Lidasa is used as a dressing. To prepare a solution, every 64 IU of lyophilisate is dissolved in 10 ml of 0.9% sodium chloride solution or boiled water, cooled to room temperature. This solution is moistened with sterile dressings folded in 4-5 layers, put them on the affected areas, covered with wax paper on top, and then fixed with a soft bandage. A single dose of the drug depends on the area of the lesion, an average of 300 IU is required per dressing. The bandage is applied for 15-18 hours daily. The duration of treatment is 15-60 days. With long-term use every 2 weeks should be done 3-4 day breaks.
If necessary, the application of Lidaza can be alternated with electrophoresis.
Basically, the drug is well tolerated, in some cases, there are allergic reactions.
With prolonged use, local irritation is possible.
Before treatment, it is recommended to conduct a test with intracutaneous administration of 20 μl of hyaluronidase.
The solution for injection is prepared using 0.9% sodium chloride solution or 0.5% procaine solution, distilled water for electrophoresis, and 0.9% sodium chloride solution for inhalation.
The drug can not be administered through the catheter, through which previously injected solutions, which include cations.
Do not inject into the tumor and areas of infectious inflammation.
Hyaluronidase enhances the action of local anesthetics, improves the absorption of drugs administered intramuscularly or subcutaneously.
Terms and conditions of storage
Store at a temperature not exceeding 15 ° C in a dark place.
Shelf life - 2 years.